Cochrane · systematic review · CD013739
Anticoagulants for people hospitalised with COVID‐19: a rapid review
Flumignan, RLG, Civile, VT, Tinôco, JD, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
10
No studies
4
Included studies
NR
No studies 4 · 28.6%Ungraded 0 · 0%Very low 5 · 35.7%Low 1 · 7.1%Moderate 2 · 14.3%High 2 · 14.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsHigher‐dose anticoagulants compared to lower‐dose anticoagulants for people hospitalised with COVID‐19
Population: people hospitalised with COVID‐19
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Higher‐dose anticoagulants vs lower‐dose anticoagulants | RR 1.03 [0.92, 1.16] | 4 studies · 4489 participants | High |
Necessity for additional respiratory support Higher‐dose anticoagulants vs lower‐dose anticoagulants | RR 0.54 [0.12, 2.47] | 3 studies · 3407 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Mortality related to COVID‐19 Higher‐dose anticoagulants vs lower‐dose anticoagulants | no estimate extracted | NR | No studies |
Deep vein thrombosis Higher‐dose anticoagulants vs lower‐dose anticoagulants | RR 1.08 [0.57, 2.03] | 4 studies · 3422 participants | Low Downgraded: imprecision |
Pulmonary embolism Higher‐dose anticoagulants vs lower‐dose anticoagulants | RR 0.46 [0.31, 0.7] | 4 studies · 4360 participants | Moderate Downgraded: risk of bias |
Major bleeding Higher‐dose anticoagulants vs lower‐dose anticoagulants | RR 1.78 [1.13, 2.8] | 4 studies · 4400 participants | Moderate Downgraded: risk of bias |
Adverse events (minor bleeding) Higher‐dose anticoagulants vs lower‐dose anticoagulants | RR 3.28 [1.75, 6.14] | 3 studies · 1196 participants | High |
Anticoagulants compared to no treatment for people hospitalised with COVID‐19
Population: people hospitalised with COVID‐19
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Anticoagulants vs no treatment | RR 0.64 [0.55, 0.74] | 3 studies · 8395 participants | Very low Downgraded: risk of bias, inconsistency |
Necessity for additional respiratory support Anticoagulants vs no treatment | no estimate extracted | NR | No studies |
Mortality related to COVID‐19 Anticoagulants vs no treatment | no estimate extracted | NR | No studies |
Deep vein thrombosis Anticoagulants vs no treatment | RR 5.67 [1.3, 24.7] | 1 study · 1403 participants | Very low Downgraded: risk of bias, imprecision |
Pulmonary embolism Anticoagulants vs no treatment | RR 24.19 [3.31, 176.53] | 1 study · 1403 participants | Very low Downgraded: risk of bias, imprecision |
Major bleeding Anticoagulants vs no treatment | RR 1.19 [0.66, 2.12] | 2 studies · 7218 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Adverse events (minor bleeding) Anticoagulants vs no treatment | no estimate extracted | NR | No studies |